As monotherapy for the first-line treatment of patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥50% of tumor cells or PD-L1 stained tumor-infiltrating immune cells covering ≥10% of the tumor area), with no EGFR or ALK genomic tumor aberrations. Here, ALK is linked to neoplasm.